🌏 Pierre Fabre Group leverages the finest elements from plants, ensuring respect for the environment and biodiversity to care for patients. Explore this TOP 3 of 239 plants cultivated by #PierreFabre 👇
Pierre Fabre Pharmaceutical Care
Fabrication de produits pharmaceutiques
We are reinventing ourselves everyday to improve everyone’s health 🌈 We are Pierre Fabre Pharmaceutical Care.
À propos
We are Pierre Fabre Pharmaceutical Care, part of the Pierre Fabre group. Thanks to our medical expertise, our creativity and unique know-how, we believe that the aknowledged therapeutic value of our products is the key to helping improve the well being of patients whether they suffer from everyday ailments, chronic diseases or more serious diseases such as certain cancers. We are reinventing ourselves everyday to improve everyone's health.
- Secteur
- Fabrication de produits pharmaceutiques
- Größe des Unternehmens
- 5 001-10 000 employés
- Siège social
- Toulouse
Nouvelles
-
Partly because of the sense of shame associated with OAB symptoms, still too few patients are at ease to express themselves to be diagnosed and treated. Create a climate of trust so they can express themselves freely! Take a look at our carousel to know more. After 42 years of expertise, Pierre Fabre Group reinforces its commitment to the field of urology through its new OAB awareness campaign.
-
Do you know which symptoms are predominant in overactive bladder syndrome? Take a look at our carousel to refresh your memory! After 42 years of expertise, Pierre Fabre Group reinforces its commitment to the field of urology through its new OAB awareness campaign. #PierreFabre
-
Pierre Fabre Pharmaceutical Care a republié ceci
Pierre Fabre Laboratories are thrilled to announce that the European Commission (EC) has granted marketing authorization (MA) for their symptomatic treatment of overactive bladder syndrome in adults 🙌. "We are delighted with this development, which will allow European patients to benefit from a new therapeutic option for overactive bladder syndrome and further strengthen our expertise of over 40 years in urology. This decision confirms Pierre Fabre Laboratories' commitment to offering patients new therapies for the management of chronic debilitating diseases." - Eric Ducournau, CEO of Pierre Fabre Laboratories. The EC's decision follows the favorable opinion issued in April by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). This approval is grounded in positive data from two pivotal, multicenter, double-blind, randomized phase 3 studies involving patients with overactive bladder symptoms. At Pierre Fabre Laboratories, we are committed to pioneering advancements across diverse health fields, delivering comprehensive solutions, and prioritizing exceptional patient care 💙. 👉 Learn more on Pierre Fabre Pharmaceutical Care #PierreFabre #NewWaysToCare #Innovation #Urology HQ--07-24-2400003
-
-
You notice urinary symptoms in a patient who's not that old? What if he/she’s suffering from overactive bladder? To know more, take a look at our carousel data. After 42 years of expertise, Pierre Fabre Group reinforces its commitment to the field of urology through its new OAB awareness campaign. #PierreFabre
-
60, 70 or 75 years old, it doesn't matter! Age no longer determines the lifestyle of your OAB patients! Help them to continue their activities! To know more, take a look at our carousel data. After 42 years of expertise, Pierre Fabre reinforces its commitment to the field of urology through its new OAB awareness campaign.
-
Work, travel, socializing - so many activities your OAB patients shouldn't miss! It’s time to improve their care and daily life! Take a look at our carousel to know more. Sustaining 42 years of expertise, Pierre Fabre Group reinforces its commitment to the field of urology through its new OAB awareness campaign.
-
Thank you to our team and to all our international subsidiaries! 🌍 We would like to express our profound gratitude to all our subsidiaries for their active participation and commitment during the #PierreFabre Pharmaceutical Care #InternationalSeminar. Your presence, ideas and collaboration are key to the success of our mission. Each contribution enriched the discussions and strengthened our common vision: improving the health and well-being of our patients around the world. 👏 We look forward to continuing on this path and innovating together for a better future. Thank you all for your commitment!
-
-
[Throwback time European Association of Urology (EAU) congress 5-8th April 2024] For the 26th consecutive time, Pierre Fabre Group was a sponsor of the European Association of Urology congress, a sign of the renewal of a commitment of more than 40 years in this field! The EAU congress is the biggest Urology congress in Europe! And it gathered doctors from all over the world. This year, #PierreFabre was delighted to host a scientific and patient centric symposium focused on the treatment personalization in male suffering from LUTS (Lower Urinary Tract Symptoms), to preserve their sexual function. A crucial topic in their care! Stavros Gravas Cosimo Denunzio Prof. Mauro Gacci Souhil Lebdai 🎥 Have a look at the video below to discover the faces of the people who make Urology at Pierre Fabre! See you next year in Madrid! 🇪🇸
-
[Throwback] 📅 From May 15th to 17th, 2024, #PierreFabre was excited to participate in the ESMO Breast Cancer congress in Berlin, Germany. As a key partner in breast oncology, we invited attendees to visit our booth and conducted interviews with key opinion leaders to discuss their practices and latest clinical advancements. 👩🔬 💬 On May 16th, Pierre Fabre held a Meet-the-Expert meeting dedicated to discussing patient needs and HCPs' expectations when treating Breast Cancer. This independent event brought together key experts from around the globe. 🌍 #ESMOBreast2024
-